#USA #Washington #Cannabinoid Research #NCCC #Standard Seed

National Compassionate Care Council and Standard Seed Partnership

The National Compassionate Care Council (NCCC), a reputable organization focused on promoting evidence-based medicinal cannabinoid policy, has officially announced its collaboration with Standard Seed Corporation (SSC), a pioneering biotechnology firm that leverages AI-driven methods in the realm of cannabinoid and botanical therapy research. This exciting partnership aims to elevate the scientific standards within the realm of cannabinoid medicine by enhancing product characterization, data quality, and evidential integrity, all of which are crucial in facilitating the seamless integration of cannabinoid therapies into the healthcare landscape.

As a part of this collaboration, NCCC will take the lead in policy advocacy efforts, while SSC will lend its scientific and technical expertise through participation in NCCC's Research and Data Collection Working Group. The primary focus for SSC will be on product characterization and traceability, alongside the establishment of scientific evidence and data standards that are applicable across various regulatory categories. This includes hemp-derived products, state-regulated cannabis products, and those regulated by the FDA as drug development.

Currently, one of NCCC's critical initiatives revolves around generating evidence that is relevant to the Substance Access Beneficiary Engagement Incentive (Substance Access BEI) facilitated by CMS Innovation Center. This optional incentive targets qualified hemp-derived products and is designed to enhance overall product quality and safety through clinician oversight and third-party testing methodologies.

With SSC’s expertise in predictive botanical AI—the platform they developed focuses on analyzing plant-derived compounds in connection to human biology—the partnership looks to tackle the variability seen in botanical source materials. Such variability often complicates the reproducibility and comparative analysis needed for clinical research. By applying computational biology alongside predictive modeling, SSC aims to pinpoint promising therapeutic candidates, generating standardized scientific insights that can complement real-world clinical evidence.

Dr. Leigh Vinocur, NCCC's Chief Medical Advisor, emphasized the importance of grounding medical cannabinoid policy in rigorous science. He noted that this collaboration with SSC adds significant scientific and technical depth to NCCC’s overarching research goals, particularly around strengthening product characterization and ensuring data quality that can better inform healthcare providers, patients, and policymakers.

In addition to their scientific contributions, SSC will also support NCCC’s Certification of Excellence product-verification initiative. This system introduces a QR-code protocol intended to bolster traceability and enhance data transparency. By implementing this system, each product can be associated with unique batch-level identifiers, providing stakeholders—ranging from clinicians and researchers to patients—unrestricted access to product information and independent laboratory analysis results. These include potency measures and contamination reports, facilitating informed decisions in cannabinoid therapy.

Dr. Suliman Sharif, CEO of Standard Seed, articulated the synergy between NCCC's objectives and SSC's capabilities, remarking that the focus on transforming real-world evidence into clinically actionable data nurtures a natural alignment for their collaborative efforts. As SSC embarks on its plant-derived therapeutic exploration, they are committed to delivering scientific tools designed to improve product characterization and the overall quality of evidence within the botanical therapeutic landscape.

This partnership is a significant stride in NCCC’s mission to fortify the scientific principles governing physician-guided cannabinoid therapies, thus promoting their incorporation into conventional healthcare settings. By combining SSC's unique research competencies with NCCC's collaborative network of healthcare stakeholders, they aim to establish standardized evidence frameworks that will benefit clinicians, researchers, policymakers, and payers as the understanding of cannabinoid healthcare and drug-development routes continues to evolve.

About NCCC

The National Compassionate Care Council is a national organization dedicated to reforming the standards of care concerning physician-guided cannabinoid therapies. By uniting a diverse range of stakeholders in the medicinal cannabis sector, NCCC engages in advocacy efforts for cannabis policy reform at both federal and state levels. Their mission emphasizes bridging the gaps between public policy and clinical practice through the promotion of scientifically sound regulations and the generation of robust real-world evidence.

About SSC

Standard Seed Corporation is at the forefront of biotechnology innovation, applying AI technologies to expedite therapeutic research across botanical sources. Their methodologies extend towards developing product verification tools aimed at enhancing standardization within natural medicines. Recently, SSC has been focusing on its flavonoid oncology program to support further drug development initiatives.